Takayuki Sumida1,2, Naoto Azuma2,3, Masafumi Moriyama2,4, Hiroyuki Takahashi1,2, Hiromitsu Asashima1,2, Fumika Honda1, Saori Abe1, Yuko Ono1,4, Tomoya Hirota1,2, Shintaro Hirata2,5,6, Yoshiya Tanaka2,5, Toshimasa Shimizu2,7, Hideki Nakamura2,7, Atsushi Kawakami2,7, Hajime Sano2,3, Yoko Ogawa2,8, Kazuo Tsubota2,8, Koufuchi Ryo2,9, Ichiro Saito2,9, Akihiko Tanaka2,4, Seiji Nakamura2,4, Etsuko Takamura2,10, Masao Tanaka2,11, Katsuya Suzuki2,12, Tsutomu Takeuchi2,12, Noriyuki Yamakawa2,13,14, Tsuneyo Mimori2,13, Akiko Ohta2,15, Susumu Nishiyama2,16, Toshio Yoshihara2,17, Yasunori Suzuki2,18, Mitsuhiro Kawano2,18, Minako Tomiita2,19, Hiroto Tsuboi1,2. 1. a Department of Internal Medicine , University of Tsukuba , Ibaraki , Japan. 2. b Clinical Practice Guideline Committee for Sjögren's Syndrome, The Research Team for Autoimmune Diseases, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW) , Tokyo , Japan. 3. c Division of Rheumatology, Department of Internal Medicine , Hyogo College of Medicine , Hyogo , Japan. 4. d Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences , Kyushu University , Fukuoka , Japan. 5. e The First Department of Internal Medicine , School of Medicine, University of Occupational and Environmental Health, Japan , Fukuoka , Japan. 6. f Department of Clinical Immunology and Rheumatology , Hiroshima University Hospital , Hiroshima , Japan. 7. g Unit of Translational Medicine, Department of Immunology and Rheumatology , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan. 8. h Department of Ophthalmology , School of Medicine, Keio University , Tokyo , Japan. 9. i Department of Pathology , Tsurumi University School of Dental Medicine , Kanagawa , Japan. 10. j Department of Ophthalmology , Tokyo Women's Medical University, School of Medicine , Tokyo , Japan. 11. k Department of Advanced Medicine for Rheumatic Diseases , Kyoto University Graduate School of Medicine , Kyoto , Japan. 12. l Division of Rheumatology, Department of Internal Medicine , School of Medicine, Keio University , Tokyo , Japan. 13. m Department of Rheumatology and Clinical Immunology , Kyoto University Graduate School of Medicine , Kyoto , Japan. 14. n Department of Rheumatology , Kyoto-Katsura Hospital , Kyoto , Japan. 15. o Division of Public Health, Department of Social Medicine , Saitama Medical University , Saitama , Japan. 16. p Kurashiki Medical Center , Okayama , Japan. 17. q Department of Otorhinolaryngology , Tokyo Women's Medical University , Tokyo , Japan. 18. r Division of Rheumatology, Department of Cardiovascular and Internal Medicine , Kanazawa University Graduate School of Medicine , Ishikawa , Japan. 19. s Department of Allergy and Rheumatology , Chiba Children's Hospital , Chiba , Japan.
Abstract
OBJECTIVES: The objective of this study is to develop clinical practice guideline (CPG) for Sjögren's syndrome (SS) based on recently available clinical and therapeutic evidences. METHODS: The CPG committee for SS was organized by the Research Team for Autoimmune Diseases, Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Japan. The committee completed a systematic review of evidences for several clinical questions and developed CPG for SS 2017 according to the procedure proposed by the Medical Information Network Distribution Service (Minds). The recommendations and their strength were checked by the modified Delphi method. The CPG for SS 2017 has been officially approved by both Japan College of Rheumatology and the Japanese Society for SS. RESULTS: The CPG committee set 38 clinical questions for clinical symptoms, signs, treatment, and management of SS in pediatric, adult and pregnant patients, using the PICO (P: patients, problem, population, I: interventions, C: comparisons, controls, comparators, O: outcomes) format. A summary of evidence, development of recommendation, recommendation, and strength for these 38 clinical questions are presented in the CPG. CONCLUSION: The CPG for SS 2017 should contribute to improvement and standardization of diagnosis and treatment of SS.
OBJECTIVES: The objective of this study is to develop clinical practice guideline (CPG) for Sjögren's syndrome (SS) based on recently available clinical and therapeutic evidences. METHODS: The CPG committee for SS was organized by the Research Team for Autoimmune Diseases, Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Japan. The committee completed a systematic review of evidences for several clinical questions and developed CPG for SS 2017 according to the procedure proposed by the Medical Information Network Distribution Service (Minds). The recommendations and their strength were checked by the modified Delphi method. The CPG for SS 2017 has been officially approved by both Japan College of Rheumatology and the Japanese Society for SS. RESULTS: The CPG committee set 38 clinical questions for clinical symptoms, signs, treatment, and management of SS in pediatric, adult and pregnant patients, using the PICO (P: patients, problem, population, I: interventions, C: comparisons, controls, comparators, O: outcomes) format. A summary of evidence, development of recommendation, recommendation, and strength for these 38 clinical questions are presented in the CPG. CONCLUSION: The CPG for SS 2017 should contribute to improvement and standardization of diagnosis and treatment of SS.
Entities:
Keywords:
Medical Information Network Distribution Service (Minds); Sjögren’s syndrome; clinical practice guideline; clinical question; systematic review